Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune will present 48-week efficacy and safety data from its Phase 2b IMPACT trial for pemvidutide at the EASL Congress 2026. The 48-week data has been selected as 'Best of EASL 2026', highlighting its significance in the scientific program. Additional poster presentations will cover new 24-week findings, including digital pathology analysis of fibrosis regression and data on cardiovascular measures.
Key figures
- Drug Name
- Pemvidutide
- Phase Of Trial
- Phase 2b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.